PARP Inhibitor Biomarkers Market Review 2024 and Forecast 2025-2035: Breast Cancer Applications Lead in Revenue, While Ovarian Cancer Emerges as the Fastest-Growing Opportunity

Market Overview - The global PARP inhibitor biomarkers market was valued at USD 0.985 billion in 2024 and is projected to reach USD 2.43 billion by 2035, growing at a CAGR of 8.57% during the forecast period (2025-2035) [3] - The market growth is driven by rising cancer rates, increasing adoption of precision medicine, advancements in genomic research, more FDA approvals, expanding indications, partnerships, collaborations, and government funding [3] Key Players - The report includes detailed profiles of major industry players such as AstraZeneca, GlaxoSmithKline (GSK), Pfizer, Inc., Merck & Co., Inc., Clovis Oncology, Novartis International AG, Roche Holding AG, and Bristol-Myers Squibb [1] Market Segmentation by Product - The kits segment accounted for the highest revenue in 2024 due to the widespread adoption of ready-to-use diagnostic kits in clinical settings [5] - The assays segment is expected to grow at the fastest CAGR during the forecast period, driven by increasing demand for high-precision testing methods and advancements in assay technologies [5] Market Segmentation by Service - The BRCA 1 & 2 testing segment generated the highest revenue in 2024, attributed to the high prevalence of BRCA mutations in breast and ovarian cancers [6] - The HRD testing segment is predicted to grow at the fastest CAGR, reflecting the focus on identifying broader patient populations beyond BRCA mutations [6] Market Segmentation by Application - The breast cancer segment led the market in revenue in 2024, driven by the high incidence of breast cancer and growing adoption of PARP inhibitors for BRCA-mutated patients [7] - The ovarian cancer segment is expected to grow at the fastest CAGR, supported by expanding use of PARP inhibitors and increasing research into biomarkers [7] Market Segmentation by End-User - Hospitals and clinics accounted for the highest revenue in 2024, due to high patient volume and preference for hospitals for cancer diagnosis and treatment services [8] - Diagnostic laboratories are predicted to grow at the fastest CAGR, driven by the outsourcing of specialized biomarker testing services and demand for high-throughput diagnostics [8] Regional Analysis - North America is anticipated to hold the highest revenue share during the forecast period, supported by well-established healthcare infrastructure, high adoption of precision medicine, and presence of leading pharmaceutical companies [9] - The Asia Pacific region is expected to grow at the fastest CAGR, driven by rapidly expanding healthcare infrastructure, increasing awareness of cancer diagnostics, rising healthcare spending, and a growing patient population [9] Technological Advancements - The introduction of the PARP Activity Screening and Inhibitor Testing Assay (PASTA) in January 2023 has advanced the understanding of PARP-related therapies and improved treatment precision [5] - Genome-wide CRISPR knockout screens have identified novel markers of prostate cancer resistance to PARP inhibitors, such as the MMS22L gene [9]